Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Frey

Podiatrist, Foot & Ankle Surgery Milford, OH Doctor of Podiatric Medicine

NPI 1629568191 CMS profile 4241948

5914 Wolfpen Pleasant Hill Rd Ste E, Milford, OH 45150

Open in the dashboard

General payments

$9,227

197 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Frey of Milford, OH is reported in the CMS Open Payments database as having received $9,227 across 197 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,073 23
2024 General $1,047 29
2023 General $1,119 27
2022 General $1,030 35
2021 General $3,343 42
2020 General $778 22
2019 General $836 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Frey
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Eric Frey were reported at $1,073. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Eric Frey Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $836 $389 $118–$1,406 $163
2020 $778 $191 $62–$691 $114
2021 $3,343 $329 $104–$1,341 $132
2022 $1,030 $419 $125–$1,611 $149
2023 $1,119 $377 $128–$1,164 $160
2024 $1,047 $394 $134–$1,168 $164
2025 $1,073 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $7,870 159 payments
  2. Medical Device Business Services, Inc. $260 1 payment
  3. Imperative Care, INc $150 1 payment
  4. Smith+Nephew, Inc. $131 5 payments
  5. Organogenesis Inc. $130 1 payment
  6. Paratek Pharmaceuticals, Inc. $82 4 payments
  7. DePuy Synthes Sales Inc. $76 4 payments
  8. MIMEDX Group, Inc. $73 4 payments
  9. Kerecis Limited $62 1 payment
  10. Crossroads Extremity Systems, LLC $56 1 payment
  11. Other $337 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,474 189 payments
  2. Travel and Lodging $1,493 7 payments
  3. Education $260 1 payment
Products named General payments · program years 2019–2025
  1. PRIME SERIES $1,602 9 payments
  2. VARIAX $1,058 10 payments
  3. AUGMENT INJECTABLE $735 16 payments
  4. VIAFLOW $727 19 payments
  5. PROPHECY $582 16 payments
  6. ALLOWRAP $474 11 payments
  7. EASYFUSE $436 7 payments
  8. CITREFIX $347 8 payments
  9. FIXOS $282 8 payments
  10. ANCHORAGE $242 7 payments
  11. Other $3,077 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

573

Median for Podiatry: 160

Drug cost

$7,229

Median for Podiatry: $2,368

Branded share of claims

2.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 46 $1,252
Ammonium Lactate Generic 108 $1,150
Colchicine Generic 21 $744
Gabapentin Generic 114 $637
Allopurinol Generic 72 $587
Ketoconazole Generic 47 $529
Diclofenac Sodium Generic 24 $516
Econazole Nitrate Generic 20 $515
Pregabalin Generic 15 $454
Terbinafine Hcl Generic 26 $232

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$81,198

Of which drugs: $164

Medicare patients

367

Average age 75

Services billed

1,939

193 women, 174 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 40%
Ischemic heart disease 36%
Chronic kidney disease 29%
Depression 25%
Heart failure 22%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 49 200 $147
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 51 206 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $34
$34 — —
KRYSTEXXA
  • Amgen Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

197 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record